ARWR
$67.27
Arrowhead Pharma
$1.74
2.66%
ARWR
Earnings Whisper ®
N/A
1st Quarter December 2019
Consensus:  ($0.03)
Revenue:  $31.00 Mil
Monday
Feb 24
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ARWR reports earnings?
Beat
Meet
Miss

Where is ARWR's stock price going from here?
Up
Flat
Down
Stock chart of ARWR
Analysts
Summary of analysts' recommendations for ARWR
Score
Grade
Pivots
Resistance
$72.25
$70.62
$68.95

$67.32

Support
$65.65
$64.02
$62.35
Tweet
Growth
Description
Arrowhead Research Corporation is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Peers
Alexion PharmaceuticalsIncyteExact SciencesCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex